関連する実験動画

Updated: Jun 28, 2026

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
07:45

A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

Published on: June 27, 2011

GM-CSFに対する抗体

S Gillis, L Garrison

    Lancet (London, England)
    |May 19, 1990
    PubMed
    まとめ

    No abstract available in PubMed .

    さらに関連する動画

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
    07:56

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

    Published on: July 22, 2019

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
    12:02

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

    Published on: November 11, 2021

    関連する実験動画

    Last Updated: Jun 28, 2026

    A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor
    07:45

    A Cell Free Assay System Estimating the Neutralizing Capacity of GM-CSF Antibody using Recombinant Soluble GM-CSF Receptor

    Published on: June 27, 2011

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells
    07:56

    Using CRISPR/Cas9 to Knock Out GM-CSF in CAR-T Cells

    Published on: July 22, 2019

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells
    12:02

    Isolation of Exosome-Enriched Extracellular Vesicles Carrying Granulocyte-Macrophage Colony-Stimulating Factor from Embryonic Stem Cells

    Published on: November 11, 2021

    関連する概念動画

    Differentiation of Common Myeloid Progenitor Cells01:15

    Differentiation of Common Myeloid Progenitor Cells

    Common myeloid progenitors (CMPs) are oligopotent cells that can differentiate into granulocytes and macrophages. Granulocytes and macrophages are essential for protecting the body against bacterial, viral, or fungal infections. They migrate from the bone marrow into the circulating blood to reach specific tissue sites where they differentiate and help in immune surveillance. However, they survive only for a few days and must be continuously made available to the organism to maintain a robust...
    Regulation of Hematopoietic Stem Cells01:01

    Regulation of Hematopoietic Stem Cells

    All blood and immune cells are produced from the multipotent hematopoietic stem cells (HSCs) by the process of hematopoiesis. However, they all have a limited life span. In addition, many are depleted in immune surveillance or combatting an injury or infection. This makes blood one of the most regenerative tissues. Hematopoiesis helps replenish these blood and immune cells, restoring the body's normal functioning. However, overproduction of blood and immune cells can make them cancerous or...

    共著者、ジャーナル、引用グラフによってこの研究に関連する記事。

    Improving outcomes in patients with Acute Kidney Injury: the impact of hospital based automated AKI alerts.

    Postgraduate medical journal·2015

    T-cell growth factors: interleukin 2.

    Immunology today·2014

    Deuterium anions in inertial electrostatic confinement devices.

    Physical review. E, Statistical, nonlinear, and soft matter physics·2009

    Near-hanging as presenting to hospitals in Queensland: recommendations for practice.

    Anaesthesia and intensive care·2006

    Abnormal cervical cytology: a risk factor for endometrial cancer recurrence.

    International journal of gynecological cancer : official journal of the International Gynecological Cancer Society·2005

    Practical and dosimetric implications of a new type of packaging for radiographic film.

    Physics in medicine and biology·2005

    1-month versus 12-month dual antithrombotic therapy after percutaneous coronary intervention in patients with atrial fibrillation (OPTIMA-AF): a multicentre, open-label, hybrid non-inferiority and superiority, randomised, controlled trial.

    Lancet (London, England)·2026

    Multidomain lifestyle intervention for the prevention of cognitive decline in at-risk older adults in Latin America (LatAm-FINGERS): a single-blind, multicentre, randomised controlled trial.

    Lancet (London, England)·2026

    Advancing the relevance of clinical trials for older patients.

    Lancet (London, England)·2026

    Temocillin versus carbapenems for bacteraemia due to third-generation cephalosporin-resistant Enterobacterales in Spain (ASTARTÉ): a multicentre, phase 3, open-label, non-inferiority, randomised clinical trial.

    Lancet (London, England)·2026

    Fixed-duration pirtobrutinib plus venetoclax-rituximab versus venetoclax-rituximab for patients with previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (BRUIN CLL-322): an open-label, multicentre, randomised, controlled, phase 3 trial.

    Lancet (London, England)·2026

    Children in all policies: lessons from a global collaboration to promote the health and wellbeing of children and future generations.

    Lancet (London, England)·2026

    Correction: An integrated automated deep learning framework for annotating tumor-infiltrating lymphocytes in lung adenocarcinoma pathology.

    Frontiers in bioinformatics·2026

    Development and pilot validation of a chemiluminescence immunoassay for monitoring immunologic changes during peanut oral immunotherapy using sIgE/sIgG4 ratio.

    Frontiers in allergy·2026

    Real-world outcomes of subcutaneous infliximab in a Middle Eastern inflammatory bowel disease cohort: a prospective study of switch and de novo treatment strategies.

    Crohn's & colitis 360·2026

    A pipeline for cell migration analysis in live-cell imaging data from human iPSC-derived forebrain assembloids.

    Frontiers in cell and developmental biology·2026

    Tislelizumab-induced myositis antibody-negative myasthenia gravis in patients with urothelial carcinoma: a case report.

    Frontiers in immunology·2026

    Case Report: Localized neutrophilic dermatosis at a split-skin donor site during PD-1 blockade: a unique immune-related adverse event.

    Frontiers in immunology·2026
    関連記事をすべて見る
    JoVE
    x logofacebook logolinkedin logoyoutube logo
    JoVEについて
    概要リーダーシップブログJoVEヘルプセンター
    著者向け
    出版プロセス編集委員会範囲と方針査読よくある質問投稿
    図書館員向け
    推薦の声購読アクセスリソース図書館諮問委員会よくある質問
    研究
    JoVE JournalMethods CollectionsJoVE Encyclopedia of Experimentsアーカイブ
    教育
    JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教員リソースセンター教員サイト
    利用規約
    プライバシーポリシー
    ポリシー
    Jove
    Visualize
    お問い合わせ